Table 5.

Genus Level Significant Differences Introduced by the Mesalazine Treatment

Bacterial taxa	Mesalazine			Placebo
	BL	12 wk		BL	12 wk
Firmicutes; Clostridia; Clostridiales; Family XIII Incertae Sedis; Incertae Sedis	0.03	0.01a		0.02	0.02
Firmicutes; Clostridia; Clostridiales; Heliobacteriaceae; Heliorestis	0.04	0.02a		0.01	0.01
Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Howardella	0.04	0.01a		0.05	0.04
Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Flavonifractor	0.71	0.42a		1.16	1.00
Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Saccharofermentans	0.32	0.04a		0.03a	0.06a
Proteobacteria; Alphaproteobacteria; Rhodospirillales; Rhodospirillaceae; Insolitispirillum	0.06	0.01a		0.06	0.04
Proteobacteria; Betaproteobacteria; Burkholderiales; Alcaligenaceae; Sutterella	0.65	0.21a		0.79	0.27
Proteobacteria; Deltaproteobacteria; Desulfuromonadales; Geobacteraceae; Geoalkalibacter	0.10	0.01a		0.01a	0.01a
Tenericutes; Mollicutes; Entomoplasmatales; Spiroplasmataceae; Spiroplasma	0.03	0.00a		0.04	0.02

^aValues indicate statistically significant difference as compared to treatment arm baseline (BL) sample.

Values show the relative abundance (%) of each genus level taxon.